Small molecule antagonists for chemokine CCR3 receptors
- 2 August 2010
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 30 (5), 778-817
- https://doi.org/10.1002/med.20181
Abstract
The chemokine receptor CCR3 is believed to play a role in the development of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis. Despite the conflicting results that have been reported regarding the importance of eosinophils and CCR3 in allergic inflammation, inhibition of this receptor with small molecule antagonists is thought to provide a valuable approach for the treatment of these diseases. This review describes the structure–activity relationships (SAR) of small molecule CCR3 antagonists as reported in the scientific and patent literature. Various chemical classes of small molecule CCR3 antagonists have been described so far, including (bi)piperidine and piperazine derivatives, N‐arylalkylpiperidine urea derivatives and (N‐ureidoalkyl)benzylpiperidines, phenylalanine derivatives, morpholinyl derivatives, pyrrolidinohydroquinazolines, arylsulfonamides, amino‐alkyl amides, imidazole‐ and pyrimidine‐based antagonists, and bicyclic diamines. The (N‐ureidoalkyl)benzylpiperidines are the best studied class in view of their generally high affinity and antagonizing potential. For many of these antagonists subnanomolar IC50 values were reported for binding to CCR3 along with the ability to effectively inhibit intracellular calcium mobilization and eosinophil chemotaxis induced by CCR3 agonist ligands in vitro. © 2009 Wiley Periodicals, Inc. Med Res Rev, 30, No. 5, 778–817, 2010Keywords
This publication has 63 references indexed in Scilit:
- Chemokine receptor antagonists: part 2Expert Opinion on Therapeutic Patents, 2009
- Chemokine receptor antagonists: Part 1Expert Opinion on Therapeutic Patents, 2009
- Chemokine receptor antagonists: overcoming developmental hurdlesNature Reviews Drug Discovery, 2008
- Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor ActivationOnline Journal of Public Health Informatics, 2007
- A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammationProceedings of the National Academy of Sciences of the United States of America, 2006
- A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor developmentThe Journal of Experimental Medicine, 2006
- Chemokine blockers – therapeutics in the making?Trends in Pharmacological Sciences, 2006
- In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031Biochemical and Biophysical Research Communications, 2006
- Identification of a Potent and Nonpeptidyl CCR3 AntagonistBiochemical and Biophysical Research Communications, 2001
- AsthmaThe New England Journal of Medicine, 2001